Lilly’s Lechleiter to chairman
Executive Summary
Lilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005
You may also be interested in...
Lilly Leadership Falls To Lechleiter In ’08 As Taurel Resigns As CEO
The appointment of Lilly President and Chief Operating Officer John Lechleiter to CEO should be a smooth transition in early 2008 when longtime chief exec Sidney Taurel retires
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.